THOUSAND OAKS, California (

TheStreet

) --

Amgen's

(AMGN) - Get Report

CEO Kevin Sharer met with his counterpart at

Actelion

to discuss Amgen's interest in the Swiss biotechnology company but no formal offer was made,

Bloomberg

reports.

Sharer met with Actelion CEO Jean-Paul Clozel last week,

Bloomberg

reports, citing three people with knowledge of the situation.

Sharer told Clozel that Amgen was studying the situation, one of the people said. Clozel wants to keep the company independent yet stay on good terms with a potential suitor, another of the people said, according to

Bloomberg

.

Actelion has a market value of 6.8 billion Swiss francs ($6.9 billion).

Bloomberg

first reported in mid-November

Amgen's interest in Actelion

.

Analysts speculate Amgen could pay $9.8 billion, or $75 a share, for Actelion,

Reuters

reports.

-- Written by Joseph Woelfel

>To contact the writer of this article, click here:

Joseph Woelfel

>To submit a news tip, send an email to:

tips@thestreet.com

.